Bicara Therapeutics Inc. announced it ended the second quarter of 2026 with $497 million in cash, providing a runway to fund operations into the first half of 2029. The company's pivotal Phase III FORTIFI-HN01 study for HPV-negative head and neck cancer remains on track for substantial enrollment by year-end 2026, with an interim analysis expected in mid-2027. Additionally, 3-year follow-up data presented at ASCO 2026 showed TGF-beta inhibition nearly doubled overall survival compared to standard of care pembrolizumab in the pivotal dose cohort. The company is also undergoing a leadership transition, elevating Ryan Cohlhepp to CEO, effective January 2027, to focus on commercial oncology execution. Operating expenses are projected to increase for the remainder of the year due to clinical operations, manufacturing, and initial commercial infrastructure investments. Bicara anticipates discl